Provided by Tiger Trade Technology Pte. Ltd.

Fractyl Health

0.5444
+0.02444.69%
Post-market: 0.56070.0163+2.99%19:59 EDT
Volume:2.15M
Turnover:1.20M
Market Cap:86.37M
PE:-0.49
High:0.5826
Open:0.5400
Low:0.5100
Close:0.5200
52wk High:2.45
52wk Low:0.3772
Shares:158.65M
Float Shares:128.00M
Volume Ratio:0.85
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1193
EPS(LYR):-1.8600
ROE:-778.33%
ROA:-74.57%
PB:-51.87
PE(LYR):-0.29

Loading ...

Fractyl Health Reports Positive One-Year Reveal-1 Open-Label Results Showing Sustained Post-Glp-1 Weight Maintenance After a Single Revita® Procedure

THOMSON REUTERS
·
Jun 04

Fractyl Health names Mike Zumdahl SVP of market access, commercial strategy

Reuters
·
Jun 01

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

THOMSON REUTERS
·
Jun 01

Fractyl Health’s Pivotal Year: Inside the Earnings Call

TIPRANKS
·
May 14

Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), UnitedHealth (UNH) and TELA Bio (TELA)

TIPRANKS
·
May 13

Fractyl Health reports Q1 EPS 6c, consensus (16c)

TIPRANKS
·
May 13

BRIEF-Fractyl Health Reports First Quarter 2026 Financial Results

Reuters
·
May 13

Fractyl Health Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Fractyl Health Q1 EPS $0.06 Beats $(0.16) Estimate

Benzinga Earnings
·
May 13

Fractyl Health Q1 FY26 turns to net income of $9.22 million; operating loss narrows 15.9% to $20.82 million

Reuters
·
May 13

Fractyl Health Inc - Reiterates Cash Runway Guidance Into Early 2027

THOMSON REUTERS
·
May 13

Fractyl Health Inc: Q1 EPS $0.06

THOMSON REUTERS
·
May 13

Press Release: Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Dow Jones
·
May 13

Fractyl Health wins Dutch clearance to start RJVA-001 first-in-human trial

Reuters
·
May 11

Fractyl Health Inc - Plans Rjva-001 Study in Australia; Regulatory Feedback Expected Q3 2026

THOMSON REUTERS
·
May 11

Fractyl Health Authorized to Initiate First-in-Human Trial of Rjva-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

THOMSON REUTERS
·
May 11

Fractyl Health Inc - First Patient Dosing and Preliminary Data for Rjva-001 Expected in H2 2026

THOMSON REUTERS
·
May 11

Fractyl Health Inc - Rejuva Clinical Development Funded Into Early 2027 With No Change to Capital Plans

THOMSON REUTERS
·
May 11

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

GlobeNewswire
·
May 11

Fractyl Health Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
May 09